Tarlatamab for relapsed/refractory small-cell lung cancer

Tarlatamab is in clinical development for the treatment of adults with refractory (unresponsive to treatment) or relapsed small cell lung cancer (SCLC) who have progressed or recurred following one platinum-based (chemotherapy) regimen and at least a prior line of therapy. SCLC is a disease in which malignant (cancer) cells form in the tissues of the lung. SCLC is a particularly aggressive form of the disease and tends to spread faster than non-SCLC, with nearly 70% of people with SCLC having metastatic disease at the time of diagnosis. Despite being both a chemo- and radiation-sensitive malignancy, SCLC recurrence occurs in most cases and negatively impacts patients' prognosis. The disease has lacked effective treatments with no therapies specifically approved to treat patients in the third line setting.